Please login to the form below

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

That combination has made prostate cancer an enticing target for drug developers and in particular those working on cancer immunotherapies, but both PD-1 and PD-L1 checkpoint inhibitors have largely ... The company thinks its phase 3 programme is the

Latest news

Soon-Shiong presents first data on cancer memory vaccine at SITC

Its ‘memory cancer vaccine’ consists of a cocktail of off-the-shelf NK cells delivered alongside low-dose chemotherapy, cytokines, yeast- and adenovirus-delivered tumour antigens and PD-1/PD-L1 ... checkpoint inhibitors – all designed to stimulate
Merck’s Bavencio joins first-line kidney cancer face-off

Taken together, while checkpoint inhibitors are now the standard of care in frontline RCC, PD-L1-positive patients tend to derive the most benefit,” notes Hsieh. ... In our view, combination with TKI could expand the clinical benefit of checkpoint
China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market. The PD-1/PD-L1 category has been transforming cancer treatment in Western markets, but so far just one of the five ... There is a huge pent-up need for new cancer immunotherapies. However, while
Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

Armo has said it thinks that the drug will increase the activity of PD-1/PD-L1 checkpoint inhibitors. ... Lilly already has a PD-L1 drug in phase I testing, while Armo also has a PD-1 antibody heading for clinical trials as well as recombinant IL-12 and
BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also not go ahead. ... 1/PD-L1 inhibitors, but the drug has been firmly relegated to speculative status.

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing
The good, the bad and the ugly

Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.
European venture funding for the life science sector

is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
Medius Deal Watch table for March 2015

170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
Deal Watch table for November 2014

PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Account Director, Healthcare Marketing Agency: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Senior Medical Writer: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Great salary and benefits

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Digital Account Director: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...